arrow
M

Munetaka Takekuma

Shizuoka Cancer Center
H指数:20
被引数:1,796

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Survival impact of pelvic radiotherapy plus chemotherapy in newly diagnosed stage IVB cervical cancer in Japan (JROSG22-1/JGOG1088S)

日本新诊断IVB期宫颈癌患者接受盆腔放疗联合化疗的生存影响(JROSG22-1/JGOG1088S)

2026-09-010
PRE
Optimal adjuvant strategy in intermediate-risk cervical cancer: a systematic review and meta-analysis

中危风险宫颈癌的最佳辅助治疗策略:一项系统评价和荟萃分析

2026-04-210
OAAI
Clinical and pathological characteristics and outcomes of small cell neuroendocrine carcinoma of the uterine cervix

子宫颈小细胞神经内分泌癌的临床与病理特征及预后

2025-07-110
PRE
Efficacy and safety of dose-dense chemotherapy for early-stage breast cancer under prophylactic pegfilgrastim administration: a systematic review and meta-analysis from clinical practice guidelines for the use of G-CSF 2022

剂量密集化疗在预防性使用培非格司亭的情况下对早期乳腺癌的疗效与安全性:一项基于《2022年G-CSF使用临床实践指南》的系统评价与荟萃分析

2025-02-120
PRE
Long-term patient-reported outcomes (PROs) with atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (CT) for metastatic, persistent or recurrent cervical cancer (R/M CC): BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase III trial

晚期、持续性或复发性宫颈癌(R/M CC)患者接受阿替利珠单抗(atezo)联合贝伐珠单抗(bev)和化疗(CT)治疗的长期能力结局(PROs):BEATcc(ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030)随机III期试验

2024-09-010
PRE
Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study

尼拉帕尼在经过大量预处理的同源重组缺陷型卵巢癌患者中的应用: 一项多中心2期研究的最终结果

2024-01-010
OAAI
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
LANCET
IF88.5
2024-01-0155
OAAI
VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
2023-12-013
OA
Updated results of a phase 2 study of niraparib in heavily pretreated high-grade serous ovarian cancer patients in Japan
2021-07-010
PREAI
Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer

尼拉帕尼在日本经过大量预处理的同源重组缺陷型卵巢癌患者中的疗效和安全性的2期单臂研究

2021-01-0110
OAAI
Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy
2020-11-306
OAAI